Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 add-on study in PNH with active hemolysis
2017-000888-33Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Primary endpoint: LDH level at study week 13. Started Oct 2017; status: completed.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2017-000888-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000888-33.